GlobeNewswire
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)
📈
AI Sentiment
Highly Positive
8/10
- Home
- ENSC
as of 12-15-2025 10:35am EST
$1.32
$0.11
-7.72%
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Chart Type:
Time Range:
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 6.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 417.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $10.96 | Next Earning Date: | 11-14-2025 |
| Revenue: | $4,487,973 | Revenue Growth: | 1.51% |
| Revenue Growth (this year): | -63.78% | Revenue Growth (next year): | N/A |
AI-Powered ENSC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 68.52%
68.52%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Ensysce Biosciences Inc. News
ENSC Breaking Stock News: Dive into ENSC Ticker-Specific Updates for Smart Investing
ACCESS Newswire
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
📈
AI Sentiment
Highly Positive
8/10
Zacks Small Cap Research
ENSC Enrolls First Patient in Critical Phase 3 Trial
📈
AI Sentiment
Highly Positive
9/10
Compare ENSC vs Leading Stocks
See how ENSC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ENSC Ensysce Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.